IMMUNOCORE HLDGS ADS/1 (6YG) — Capital Reinvestment Ratio
IMMUNOCORE HLDGS ADS/1 (6YG) has a Capital Reinvestment Ratio of 0.05x as of June 2026, meaning it reinvests 0% of its operating cash flow (€15.93 Million) in capital expenditures (€786.00K). Check IMMUNOCORE HLDGS ADS/1 (6YG) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
IMMUNOCORE HLDGS ADS/1 Capital Reinvestment Ratio (2023–2024)
This chart tracks IMMUNOCORE HLDGS ADS/1's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see IMMUNOCORE HLDGS ADS/1 cash conversion from operations.
Annual Capital Reinvestment Ratio for IMMUNOCORE HLDGS ADS/1 (2023–2024)
Year-by-year Capital Reinvestment Ratio for IMMUNOCORE HLDGS ADS/1 from 2023 to 2024. See 6YG free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.20x | €26.06 Million | €5.17 Million | ▼ -89.2% |
| 2023 | 1.85x | €2.94 Million | €5.42 Million | — |